Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 27;12:929123. doi: 10.3389/fonc.2022.929123

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Keller, Eleveld, Schild, van den Handel, van den Boogaard, Amo-Addae, Eising, Ober, Koopmans, Looijenga, Tytgat, Ylstra, Molenaar, Dolman and van Hooff

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Validation of correlation between 11q loss and CHK1 inhibitor sensitivity. (A) Volcano plot of differential drug sensitivities in 11q deleted versus 11q wild type neuroblastoma cell lines included in the Wellcome Trust Sander Institute dataset. The y-axis shows the inverted p-value (-log10) as derived by student’s t-test and the x-axis shows the effect magnitude (mean IC50 of 11q deleted – mean IC50 of 11q wild type cell lines). Each dot represents one compound and those targeting CHK1 are highlighted in red. (B) Box plot of IC50 values of NB cell lines included in the Wellcome Trust Sanger Institute dataset after exposure to CHK1 inhibition with MK-8776 (p = 0.0002), AZD7762 (p = 0.0003) or Wee1 Inhibitor (p = 0.0071). Statistical significance is reached (Mann-Whitney U test).